COVID-19 infection in cancer patients: the effect of Hepatitis B immunization

Introduction: To investigate the clinical characteristics and outcomes of cancer patients with COVID-19 infections and evaluate the effect of hepatitis B immunization status on susceptibility to COVID-19 infection and mortality risk. Materials and methods: The records of 1,515 patients who presented to the Medical Oncology clinic between March 2020 and December 2020 were analysed retrospectively. The demographic and clinical characteristics and laboratory findings of cancer patients with (case group) and without (control group) COVID-19 infection were compared. Results: Of the 1,515 patients, 153 (10.1%) had been diagnosed with COVID-19, and the median age of cancer patients with COVID-19 infection was 53.9 (range; 18–82) years. The most common types of cancer were breast cancer (26.2%), gastrointestinal system cancers (22.3%), genitourinary-system cancers (16.5%) and lung cancer (15.5%). The presence of metastatic disease [hazard ratio (HR): 0.09, 95% CI (0.01–0.83), (p = 0.03)] and receipt of palliative chemotherapy in the cancer patients with COVID-19 infections [HR: 0.1, 95% CI (0.01–0.69), (p = 0.02)] were identified as prognostic factors in multivariate analysis as univariate analysis did not indicate palliative treatment as a prognostic factor. When the case group and control groups were compared in terms of hepatitis B immunization status (p = 0.24), no statistically significant difference was identified between the two groups. Furthermore, hepatitis B immunization status (p = 0.37) were not found to be associated with COVID-19-related mortality risk. Conclusion: Hepatitis B immunization status were not associated with the risk of COVID-19 transmission and mortality. The present study identified the presence of metastatic disease and palliative chemotherapy as negative and positive prognostic factors, respectively

Frequency and relationship of ABO blood groups in patients with nephrotic syndrome

Aim of the study: To investigate the frequency of ABO blood groups and the relationship between nephrotic syndrome (NS) and blood groups in patients with NS.Material and methods: 199 patients with a diagnosis of NS and 200 healthy individuals, who applied to Dicle University Faculty of Medicine, Department of Nephrology between 2016 and 2020, and whose blood group information was in the records, were included in the study as the control group. This study was carried out retrospectively using data from the file registration system in our hospital.Results: In the study, there were 199 patients: 52.8% (n = 105) male and 47.2% (n = 94) female and 200 healthy individuals: 47.5% male (n = 95) 52.5% female (n = 105). The mean age of the patients was 35.79 ± 12.21 (min-max: 17–71), and the mean proteinuria was 7.08 ± 4.33 (min-max: 3.50–25.50). There was no difference between sick and healthy individuals in terms of age or sex (p > 0.05). It was determined that 43.2% of the patients had blood group A, 26.1% blood group O, 25.1% blood group B, and 5.5% blood group AB. There was no significant difference between blood groups of patients with NS and individuals in the healthy group (p > 0.05). Membranous glomerulonephritis (MGN) (27.9%) was most common in blood group A; FSGS was detected most frequently in blood groups B (46.0%), O (28.8%), and AB (36.4%). The most common cause of NS was focal segmental glomerulosclerosis (FSGS) in 31.2% (n = 62), and MGN was the second common cause in 19.1% (n = 38), blood group B (37.1%) in FSGS, blood group O (46.7%) in systemic lupus erythematosus, MGN (63.2%), IgA nephropathy (50%), and MPGN (52.2%) was found most frequently in blood group A. Conclusions: We did not find a significant relationship between the blood group and NS in our study

The prevalence, clinical and pathological characteristics of primary focal segmental glomerulosclerosis in Turkish adults: The data from TSN-Gold (Turkish society of nephrology glomerular diseases) working group

...ERA; EDT

Characteristics of primary glomerular diseases patients with hematuria in Turkey: the data from TSN-GOLD Working Group

Purpose Hematuria is one of the most common laboratory findings in nephrology practice. To date, there is no enough data regarding the clinical and histopathologic characteristics of primary glomerular disease (PGD) patients with hematuria in our country. Methods Data were obtained from national multicenter (47 centers) data entered into the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) database between May 2009 and June 2019. The data of all PGD patients over the age of 16 years who were diagnosed with renal biopsy and had hematuria data were included in the study. Demographic characteristics, laboratory and biopsy findings were also recorded. Results Data of 3394 PGD patients were included in the study. While 1699 (50.1%) patients had hematuria, 1695 (49.9%) patients did not have hematuria. Patients with hematuria had statistically higher systolic blood pressure, serum blood urea nitrogen, creatinine, albumin, levels and urine pyuria. However, these patients had statistically lower age, body mass index, presence of hypertension and diabetes, eGFR, 24-h proteinuria, serum total, HDL and LDL cholesterol, and C3 levels when compared with patients without hematuria. Hematuria was present 609 of 1733 patients (35.8%) among the patients presenting with nephrotic syndrome, while it was presented in 1090 of 1661 (64.2%) patients in non-nephrotics (p < 0.001). Conclusion This is the first multicenter national report regarding the demographic and histopathologic data of PGD patients with or without hematuria. Hematuria, a feature of nephritic syndrome, was found at a higher than expected in the PGDs presenting with nephrotic syndrome in our national database

Characteristics of primary glomerular diseases patients with hematuria in Turkey: the data from TSN-GOLD Working Group

Purpose Hematuria is one of the most common laboratory findings in nephrology practice. To date, there is no enough data regarding the clinical and histopathologic characteristics of primary glomerular disease (PGD) patients with hematuria in our country. Methods Data were obtained from national multicenter (47 centers) data entered into the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) database between May 2009 and June 2019. The data of all PGD patients over the age of 16 years who were diagnosed with renal biopsy and had hematuria data were included in the study. Demographic characteristics, laboratory and biopsy findings were also recorded. Results Data of 3394 PGD patients were included in the study. While 1699 (50.1%) patients had hematuria, 1695 (49.9%) patients did not have hematuria. Patients with hematuria had statistically higher systolic blood pressure, serum blood urea nitrogen, creatinine, albumin, levels and urine pyuria. However, these patients had statistically lower age, body mass index, presence of hypertension and diabetes, eGFR, 24-h proteinuria, serum total, HDL and LDL cholesterol, and C3 levels when compared with patients without hematuria. Hematuria was present 609 of 1733 patients (35.8%) among the patients presenting with nephrotic syndrome, while it was presented in 1090 of 1661 (64.2%) patients in non-nephrotics (p < 0.001). Conclusion This is the first multicenter national report regarding the demographic and histopathologic data of PGD patients with or without hematuria. Hematuria, a feature of nephritic syndrome, was found at a higher than expected in the PGDs presenting with nephrotic syndrome in our national database

Characteristics of primary glomerular diseases patients with hematuria in Turkey: The data from TSN-GOLD Working Group

Purpose Hematuria is one of the most common laboratory findings in nephrology practice. To date, there is no enough data regarding the clinical and histopathologic characteristics of primary glomerular disease (PGD) patients with hematuria in our country. Methods Data were obtained from national multicenter (47 centers) data entered into the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) database between May 2009 and June 2019. The data of all PGD patients over the age of 16 years who were diagnosed with renal biopsy and had hematuria data were included in the study. Demographic characteristics, laboratory and biopsy findings were also recorded. Results Data of 3394 PGD patients were included in the study. While 1699 (50.1%) patients had hematuria, 1695 (49.9%) patients did not have hematuria. Patients with hematuria had statistically higher systolic blood pressure, serum blood urea nitrogen, creatinine, albumin, levels and urine pyuria. However, these patients had statistically lower age, body mass index, presence of hypertension and diabetes, eGFR, 24-h proteinuria, serum total, HDL and LDL cholesterol, and C3 levels when compared with patients without hematuria. Hematuria was present 609 of 1733 patients (35.8%) among the patients presenting with nephrotic syndrome, while it was presented in 1090 of 1661 (64.2%) patients in non-nephrotics (p < 0.001). Conclusion This is the first multicenter national report regarding the demographic and histopathologic data of PGD patients with or without hematuria. Hematuria, a feature of nephritic syndrome, was found at a higher than expected in the PGDs presenting with nephrotic syndrome in our national database

Characteristics of primary glomerular disease patients with hematuria in Turkey: The data from TSN-Gold working group

...ERA EDT

Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey

Background. Chronic kidney disease (CKD) and immunosuppression, such as in renal transplantation (RT), stand as one of the established potential risk factors for severe coronavirus disease 2019 (COVID-19). Case morbidity and mortality rates for any type of infection have always been much higher in CKD, haemodialysis (HD) and RT patients than in the general population. A large study comparing COVID-19 outcome in moderate to advanced CKD (Stages 3-5), HD and RT patients with a control group of patients is still lacking. Methods. We conducted a multicentre, retrospective, observational study, involving hospitalized adult patients with COVID-19 from 47 centres in Turkey. Patients with CKD Stages 3-5, chronic HD and RT were compared with patients who had COVID-19 but no kidney disease. Demographics, comorbidities, medications, laboratory tests, COVID-19 treatments and outcome [in-hospital mortality and combined in-hospital outcome mortality or admission to the intensive care unit (ICU)] were compared. Results. A total of 1210 patients were included [median age, 61 (quartile 1-quartile 3 48-71) years, female 551 (45.5%)] composed of four groups: Control (n = 450), HD (n = 390), RT (n = 81) and CKD (n = 289). The ICU admission rate was 266/ 1210 (22.0%). A total of 172/1210 (14.2%) patients died. The ICU admission and in-hospital mortality rates in the CKD group [114/289 (39.4%); 95% confidence interval (CI) 33.9-45.2; and 82/289 (28.4%); 95% CI 23.9-34.5)] were significantly higher than the other groups: HD = 99/390 (25.4%; 95% CI 21.3-29.9; P<0.001) and 63/390 (16.2%; 95% CI 13.0-20.4; P<0.001); RT = 17/81 (21.0%; 95% CI 13.2-30.8; P = 0.002) and 9/81 (11.1%; 95% CI 5.7-19.5; P = 0.001); and control = 36/450 (8.0%; 95% CI 5.8-10.8; P<0.001) and 18/450 (4%; 95% CI 2.5-6.2; P<0.001). Adjusted mortality and adjusted combined outcomes in CKD group and HD groups were significantly higher than the control group [hazard ratio (HR) (95% CI) CKD: 2.88 (1.52- 5.44); P = 0.001; 2.44 (1.35-4.40); P = 0.003; HD: 2.32 (1.21- 4.46); P = 0.011; 2.25 (1.23-4.12); P = 0.008), respectively], but these were not significantly different in the RT from in the control group [HR (95% CI) 1.89 (0.76-4.72); P = 0.169; 1.87 (0.81-4.28); P = 0.138, respectively]. Conclusions. Hospitalized COVID-19 patients with CKDs, including Stages 3-5 CKD, HD and RT, have significantly higher mortality than patients without kidney disease. Stages 3-5 CKD patients have an in-hospital mortality rate as much as HD patients, which may be in part because of similar age and comorbidity burden. We were unable to assess if RT patients were or were not at increased risk for in-hospital mortality because of the relatively small sample size of the RT patients in this study